Valuation
- Market cap
- 53,856,000
- Revenue TTM
- $0
- Net income TTM
- $-56,030,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 616,000
- Avg volume
- 96,874
- Day's range
- $7.27 – $7.47
- Shares out
- 7,388,000
- Stochastic %K
- 25%
- Beta
- 0.40
- Analysts
- Hold
- Price target
- $6.00
Company profile
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2...
Show more
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 822 5600
- Website
- https://www.kezarlifesciences.com
- Address
- 4000 Shoreline Court, Suite 300, South San Francisco, United States
Latest news
No headlines yet.
